Chiltern Achieves Supplementary Accreditation From the Medicines and Healthcare Products Regulatory Agency

Jun 07, 2010, 09:51 ET from Chiltern

LONDON, June 7 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), has announced that Chiltern Early Phase Limited, based in Ninewells Hospital and Medical School in Dundee, Scotland, has achieved Supplementary Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA).

Dr Brian Sanderson, Medical Director, Chiltern Early Phase, explains, "In November 2007, the MHRA launched a voluntary accreditation scheme for units conducting Phase 1 studies in the UK. The scheme is designed to provide assurance to sponsors and participants that the accredited units meet satisfactory standards of quality and safety with adherence to Good Clinical Practice as well as best medical practice for subject safety."

There are two tiers of accreditation:

  • Standard Accreditation – units accredited to this level will be accredited to carry out all Phase 1 trials except those First in Human (FIH) trials requiring Clinical Trial Expert Advisory Group of the Commission of Human Medicines (CTEAG) review.
  • Supplementary Accreditation - units accredited to this level will be accredited to carry out all Phase 1 trials including those First in Human (FIH) trials requiring CTEAG review.

Glenn Kerkhof, Chiltern CEO, stated, "With the achievement of Supplementary Accreditation, Chiltern Early Phase is uniquely placed to offer a full range of early phase FIH/exploratory development studies including Proof of Concept/Translational Medicine studies performed to the highest standards of safety and quality. This accreditation augments our collaboration with the Tayside Academic Health Sciences Centre including the Clinical Research Centre for Proof of Concept studies."

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries, has 24 offices and legal entities within 21 countries, resources in 37 countries and employs nearly 1,400 people globally. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information:


Natalie Chong

Susan Ojanen

Marketing Director

Marketing Associate

Chiltern International Ltd., UK

Chiltern International Inc., USA

Tel: +44 (0) 1753 512 000

Tel: +1 (423) 968 9533

SOURCE Chiltern